Kiyatec’s 3D Predict Glioma Test Shows Improved Survival Outcomes for Glioma Patients

Predictive diagnostics company Kiyatec has revealed data demonstrating that its 3D Predict Glioma test significantly improved survival outcomes in patients with high-grade glioma (HGG) by accurately predicting their response to chemotherapy. Published in Scientific Reports, the study showed that patients who responded to the test experienced a median progression-free survival increase of 5.8 months and an overall survival increase of 7.6 months compared to non-responders.

The study (NCT03561207) involved 102 newly diagnosed HGG patients, a group typically facing a poor prognosis. The 3D Predict Glioma test works by taking cancer cells from patients and cultivating them in a 3D cell culture that mimics natural human cell interactions. These cultures are then treated with radiation and temozolomide, the standard care for HGG.

Kiyatec highlighted that HGG patients whose tumors are unresponsive to temozolomide could be better served by enrolling in clinical trials or receiving alternative treatments that may offer more significant benefits.

High-grade glioma is an aggressive, fast-growing brain tumor originating from glial cells that support nerve cells in the brain. It includes glioblastoma, one of the most severe forms, known for its rapid progression and resistance to treatment.

In 2020, there were 27,449 cases of HGG across major markets, including the US, UK, and China, according to GlobalData epidemiologists.

Kiyatec CEO Eric Perreault called the study’s publication a "significant milestone" for both the company and the broader field of functional precision oncology. He noted that the 3D Predict Glioma test marks a new era in individualized treatment for HGG patients, offering renewed hope.

Kiyatec, based in Greenville, US, partnered with AstraZeneca in May 2023 to evaluate the therapeutic efficacy of preclinical assets using another test in Kiyatec's portfolio, KIYA-Predict. This proprietary platform accelerates oncology drug development by providing precise therapeutic response insights using human tumor tissue.

In 2022, Kiyatec raised $18 million in a Series C funding round led by Bruker, Seae Ventures, VentureSouth, and LabCorp. The company has also recently secured investments from The Brain Tumor Investment Fund and the Sontag Innovation Fund, though the amounts were not disclosed.